Q32 Bio to present bempikibart alopecia data at EADV 2026

Q32 Bio Inc. will present 36-week results from its Phase 2a SIGNAL-AA Part B trial of bempikibart in severe alopecia areata at the EADV Congress in Vienna on Sept. 30, 2026. The data will include early findings from a 16-week off-drug period, indicating hair regrowth that persisted after treatment stopped.